AGCT is a perspective and ambitious R&D company that has united the leading specialists in clinical medicine, oncology, hematology, stem cell transplantation, cell therapy and molecular biology. Research, development and eventual commercialization of the genome editing techniques for cure of socially significant diseases is our main priority.
AGCT works in the close collaboration with the Pavlov First State Medical University of Saint Petersburg and the University Medical Center Hamburg-Eppendorf. AGCT is a resident of the Skolkovo Innovation Center in Moscow, Russia and a resident of the ITMO University Technopark.
AGCT LLC is based in Saint Petersburg. The core members of the team are the employees of the Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Pavlov First State Medical University of St. Petersburg. The company is fully associated with the University and closely collaborates with its clinical departments and laboratories.
In 2016, AGCT was one of the winners in the Skolkovo Startup Village Contest, in 2017 the Company attracted its main investor – the Russian Venture Company (RVC JSC) and in 2019 received a large grant from the Skolkovo Innovation Centre for future development.